Breast Cancer Treatment Strategies and Clinical Research

Neoadjuvant Chemotherapy and Response Metrics

Neoadjuvant chemotherapy is frequently used to reduce tumor size, which can increase the likelihood of successful breast conservation. A critical metric in evaluating the effectiveness of this approach is the pathologic complete response (pCR). A pCR is achieved when no residual invasive cancer is found in the surgical specimen after neoadjuvant treatment. Achieving pCR is a powerful prognostic indicator, as it is strongly associated with improved long-term clinical benefits and overall survival. Conversely, if cancer remains, clinicians assess the residual cancer burden (RCB) to guide subsequent adjuvant therapy.

Subtype-Specific Neoadjuvant Approaches

Treatment regimens are heavily influenced by the molecular subtype of the breast cancer:

• HER2-Positive Breast Cancer: For tumors overexpressing the HER2 protein, neoadjuvant regimens typically combine chemotherapy with targeted monoclonal antibodies, such as trastuzumab and pertuzumab. Recent updates in clinical guidelines emphasize the use of highly effective agents like fam-trastuzumab deruxtecan-nxki for high-risk cases.
• Triple-Negative Breast Cancer (TNBC): Because TNBC lacks estrogen, progesterone, and HER2 receptors, it relies heavily on chemotherapy and, more recently, immunotherapy. Research such as the KEYNOTE-522 study has demonstrated that adding the immunotherapy agent pembrolizumab to neoadjuvant chemotherapy can significantly improve event-free survival.

Endocrine Therapy and Biomarkers

For patients with hormone receptor-positive (HR+) breast cancer (also referred to as estrogen receptor-positive (ER+)), endocrine therapy is a cornerstone of long-term management.

Standard Agents and Extensions

Tamoxifen is a widely used selective estrogen receptor modulator (SERM). Clinical trials, such as the ATLAS trial, have provided evidence regarding the benefits of extending tamoxifen treatment to 10 years for certain patients to further reduce recurrence risk.

In postmenopausal women, Aromatase Inhibitors (AIs) are frequently utilized to lower estrogen levels. These include:

• Anastrozole
• Letrozole
• Exemestane

Large-scale trials like ATAC and BIG 1-98 have compared AIs to tamoxifen, often demonstrating the superior efficacy of AIs in preventing recurrence, although clinicians must monitor patients for side effects such as decreased bone mineral density.

The Role of Predictive Biomarkers

To move toward more personalized medicine, clinicians use various predictive biomarkers to determine which patients will benefit most from specific therapies. These include:

1. HER-2 status: Determines eligibility for anti-HER2 targeted therapies.
2. p53 expression: Can indicate specific mutation patterns and aggressive behavior.
3. Gene Expression Profiles: Tests such as the 21-gene test or PAM50 analyze the molecular signature of the tumor to predict the likelihood of recurrence and the necessity of adjuvant chemotherapy.

Exam Tip: When evaluating a patient's prognosis after neoadjuvant therapy, always look for the pathologic complete response (pCR) status. A pCR is a strong surrogate marker for improved long-term survival, especially in HER2-positive and TNBC subtypes.

---

References NCCN Guidelines® Breast Cancer Version 8.2026, 10/08/26.